Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells. - Wikidata - awgldk - TriplyDB

Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells.

Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells.

http://www.wikidata.org/entity/Q37483111

about

mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and aging Diffuse Cystic Lung Disease. Part I.Progesterone and estradiol synergistically promote the lung metastasis of tuberin-deficient cells in a preclinical model of lymphangioleiomyomatosis Rapamycin-insensitive up-regulation of adipocyte phospholipase A2 in tuberous sclerosis and lymphangioleiomyomatosis.Rapamycin-resistant poly (ADP-ribose) polymerase-1 overexpression is a potential therapeutic target in lymphangioleiomyomatosis.Effect of polyunsaturated fatty acids and their metabolites on bleomycin-induced cytotoxic action on human neuroblastoma cells in vitro.Lymphangioleiomyomatosis Biomarkers Linked to Lung Metastatic Potential and Cell Stemness Tuberous sclerosis complex 2 loss increases lysophosphatidylcholine synthesis in lymphangioleiomyomatosis.Identification of potential drug targets for tuberous sclerosis complex by synthetic screens combining CRISPR-based knockouts with RNAi.Estrogen maintains myometrial tumors in a lymphangioleiomyomatosis model Solitary extrapulmonary lymphangioleiomyomatosis of the liver: A case report and literature review Proapoptotic protein Bim attenuates estrogen-enhanced survival in lymphangioleiomyomatosis Resolution of Cancer-Promoting Inflammation: A New Approach for Anticancer Therapy.Oncogenic effects of urotensin-II in cells lacking tuberous sclerosis complex-2 Tuberous Sclerosis Complex: new criteria for diagnostic work-up and management.Lymphangioleiomyomatosis: New Treatment Perspectives.Metabolic Impact of Rapamycin (Sirolimus) and B-Estradiol Using Mouse Embryonic Fibroblasts as a Model for Lymphangioleiomyomatosis.Minireview: Lymphangioleiomyomatosis (LAM): The "Other" Steroid-Sensitive Cancer.Tuberous sclerosis complex: From molecular biology to novel therapeutic approaches.Rapamycin combined with celecoxib enhanced antitumor effects of mono treatment on chronic myelogenous leukemia cells through downregulating mTOR pathway.Focal Adhesion- and IGF1R-Dependent Survival and Migratory Pathways Mediate Tumor Resistance to mTORC1/2 Inhibition.Improved detection of synthetic lethal interactions in Drosophila cells using variable dose analysis (VDA).Emerging biomarkers of lymphangioleiomyomatosis.The LAM Lung Cell and Its Human Cell Models.Systems biology approach reveals a link between mTORC1 and G2/M DNA damage checkpoint recovery

P2860

Q28081442-C14EB273-10B0-4B4F-9A1A-46E18ED76D50 Q33722950-A4F6CA20-FA93-4AA5-9540-9E8A0275E58B Q34204852-13F64A30-082C-4AF9-8379-802992A139E6 Q34408059-8117ECB1-EADF-484B-9A72-2E67BD6AF787 Q34924914-CDACBB5C-FC86-4B33-ABAE-EE798E930188 Q35533273-D1EDC45F-B7B4-4760-B96F-6AC30FFEE30D Q35689467-09E71E47-C7D4-47A4-9BF7-B8A2B309BA36 Q36049513-5E909E55-9D9B-4BA4-87F6-EF5002955DA0 Q36274085-7C956193-4002-4A02-8714-9779BE67F9B7 Q37193373-71A09B88-1E72-44E5-A827-D5C12A0D193A Q37204161-B3C961FB-FAA4-41FC-8A42-083913C1F4EA Q37417526-4A29715D-270F-45C1-88F4-9B75D027CB97 Q37619977-FBD625D5-6A42-439E-954A-13BDED4CA44B Q37641575-56BD76A4-265C-4B8B-AD63-A498BD4B0EC3 Q38414596-7CEC3FE3-F33E-4B25-B276-D39FE31A317E Q38484497-A7003829-D611-4533-8DB9-AF0BFC5EF612 Q38675393-B7227BB2-FCF1-46E4-9E95-395A78B09883 Q38895095-4DAB906F-8E1F-4A83-B541-E98824C62E77 Q38994919-AB01F8AB-95ED-44EA-931D-7D8729A3C935 Q39010100-68BA5E76-622F-4E9D-B887-E9057E6C2C01 Q48011517-09ABAB25-0BCC-4BF0-A311-2D30A5E7C8A9 Q48221452-1A1BF846-2BE1-46FA-86C9-7C9888B5A4E9 Q49679457-3B898C43-DB8B-4532-A3CD-516055BBFCB4 Q50181460-F4009D19-D3DA-40B5-AAD8-35A8D51ED610 Q59126224-AF885079-8B5E-4973-9A49-4CB477D909BC

P2860

Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells.

http://www.wikidata.org/entity/Q37483111

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 06 January 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Estradiol and mTORC2 cooperate ...... s in TSC2-deficient LAM cells.

@en

Estradiol and mTORC2 cooperate ...... s in TSC2-deficient LAM cells.

@nl

type

label

Estradiol and mTORC2 cooperate ...... s in TSC2-deficient LAM cells.

@en

Estradiol and mTORC2 cooperate ...... s in TSC2-deficient LAM cells.

@nl

prefLabel

Estradiol and mTORC2 cooperate ...... s in TSC2-deficient LAM cells.

@en

Estradiol and mTORC2 cooperate ...... s in TSC2-deficient LAM cells.

@nl

P1433

Q37483111-8695A0C4-1C62-4FB2-991F-BE95B2C5142C

P1476

Q37483111-7099033D-6B33-475C-A944-E19A8E42C4B7

P2093

Q37483111-01D981E3-F275-4290-99C4-DCDD0CD549C6

Q37483111-06BD7F32-B21D-4BBA-B0FE-1F96CDEFF094

Q37483111-2137C3B5-FFD6-4450-99FC-321AFB912B2F

Q37483111-27DF0FD4-FADD-430B-9632-86332F031658

Q37483111-37E449F5-11CC-4330-81BB-0CB641C53551

Q37483111-389A772A-29C5-4EF3-A9CC-EE8BB01A2C19

Q37483111-389DC3F8-652F-4FB6-BBB6-D918142B6E45

Q37483111-3F7CC7B3-2192-4F3D-9A02-30933AE821E8

Q37483111-4152A122-D25C-4B5E-9C77-B4A310D7A635

Q37483111-500D0593-B8D7-47B7-9982-3E23AFA37A0C

P2860

Q37483111-02D5BB23-E314-4E83-B468-7E34EE28B54B

Q37483111-036D57C7-3E9E-4175-BCFB-A9F769154B92

Q37483111-1073F15B-848F-4D8B-8931-C72A74BD9F4F

Q37483111-1508906D-1A01-4295-AFA6-179ED6EE5A91

Q37483111-1AEF09B5-0B43-49C9-8F65-AF84F3D8F8F4

Q37483111-2497601E-9CB7-4B2E-985A-7862D52F574D

Q37483111-3BBCB66D-68F4-4725-8E71-22897DF82EBA

Q37483111-3D1E27C4-5440-4C50-B6D7-0E625EFA6010

Q37483111-4BF989A3-2EB3-47B9-9717-3F7D1BD30074

Q37483111-518D1AAE-64E8-4919-B718-FA5C15FEFB85

P304

Q37483111-BDE89BBE-1639-4C7E-8170-9CE4827ACDE8

P31

Q37483111-7A0CBF4A-3A55-4B29-9332-C06AA21B1B7C

P356

Q37483111-AB0887B5-FCD0-47A5-81EF-5606B1AB042A

P407

Q37483111-F570C567-C958-4718-8F9F-3CF5E0FA5743

P433

Q37483111-A2A7C2AE-A99A-4FE9-87C8-A6FDEF24A20E

P478

Q37483111-C6C1499A-3569-4EFB-B279-51ED17E9C675

P50

Q37483111-504BA81E-4437-4D8C-B2F5-DFD26741687E

P577

Q37483111-716A0038-8667-4930-92C6-0490C604E494

P5875

Q37483111-F9C93BC8-13FC-4618-9CE8-80589F36D018

P698

Q37483111-C9F5A6AB-CF55-4531-93FD-8BD695E21EBA

P932

Q37483111-73CDEF0B-9C05-4D79-82B8-DBE1FC80F7A5

P356

P1433

Journal of Experimental Medicine

P1476

Estradiol and mTORC2 cooperate ...... s in TSC2-deficient LAM cells.

@en

P2093

Alfredo Csibi

http://www.w3.org/2001/XMLSchema#string

Anna Planaguma

http://www.w3.org/2001/XMLSchema#string

Bruce D Levy

http://www.w3.org/2001/XMLSchema#string

Carmen Priolo

http://www.w3.org/2001/XMLSchema#string

Chenggang Li

http://www.w3.org/2001/XMLSchema#string

Chin-Lee Wu

http://www.w3.org/2001/XMLSchema#string

David Kwiatkowski

http://www.w3.org/2001/XMLSchema#string

Elizabeth Petri Henske

http://www.w3.org/2001/XMLSchema#string

Elliot Israel

http://www.w3.org/2001/XMLSchema#string

Erik Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Hamartin, the product of the tuberous sclerosis 1 (TSC1) gene, interacts with tuberin and appears to be localized to cytoplasmic vesicles

Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs

Efficacy and safety of sirolimus in lymphangioleiomyomatosis.

Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression

Real-time monitoring of tumorigenesis, dissemination, & drug response in a preclinical model of lymphangioleiomyomatosis/tuberous sclerosis complex

Organization of GC/MS and LC/MS metabolomics data into chemical libraries

Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation

Therapeutic trial of metformin and bortezomib in a mouse model of tuberous sclerosis complex (TSC)

Tsc2(+/-) mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background

Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent

P304

15-28

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1084/JEM.20131080

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

211

http://www.w3.org/2001/XMLSchema#string

P50

Andrey Parkhitko

P577

2014-01-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259608259

http://www.w3.org/2001/XMLSchema#string

P698

24395886

http://www.w3.org/2001/XMLSchema#string

P932

3892971

http://www.w3.org/2001/XMLSchema#string